Preservative-free preparation may improve adherence

Article

Tafluprost 0.0015% is safe, effective and well-tolerated in routine clinical practice

To date, prostaglandin analogues (PGAs) have become the most common medical treatment worldwide to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. PGAs have a strong, sustained and stable IOPlowering effect and a generally well tolerated systemic safety profile.

Tafluprost 0.0015% is the first and only PGA that is available in a preservative-free formulation. We evaluated the efficacy, local tolerability and safety of preservative-free tafluprost 0.0015% (Taflotan) in a routine clinical setting.1

Recent Videos
3 experts are featured in this series.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.